Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Patricia Pozo-Rosich, Jessica Ailani, Messoud Ashina...
https://pubmed.ncbi.nlm.nih.gov/37516125/Actively Recruiting
Led by IRCCS National Neurological Institute "C. Mondino" Foundation · Updated on 2025-03-18
30
Participants Needed
1
Research Sites
17 weeks
Total Duration
Researchers are studying the effects of atogepant, a CGRP receptor antagonist, on patients with high-frequency episodic migraine who experience 8 to 14 migraine days per month. The study aims to understand how atogepant changes brain function and biochemical markers related to migraine, helping to identify predictors of treatment response and potential alternative therapies for those who do not benefit from it. This research focuses on the neurophysiological and biomolecular mechanisms involved in migraine and the impact of atogepant on these pathways. Participants will take atogepant 60 mg daily for three months. The study involves detailed neurofunctional assessments, including High-Density EEG, nociceptive reflexes, and visual evoked potentials, as well as biochemical tests measuring gene expression of endocannabinoid enzymes, plasma levels of CGRP and PACAP, and specific migraine-related microRNAs. These evaluations occur at the start and end of the treatment period to compare changes over time. During the study, patients will undergo clinical evaluations, biochemical sampling between 9 and 11 a.m. to avoid circadian influence, and various neurophysiological recordings. Researchers will track outcomes such as the temporal summation threshold of the RIII reflex and gene expression of MAGL, among others. The study will also monitor safety and treatment effects through a comprehensive set of biochemical and neurofunctional markers, with a total participation duration of three months under close observation.
CONDITIONS
Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine
F
Francescantonio Cammarota, MD
C
Cinzia Fattore
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
IRCCS National Neurological Institute "C. Mondino" Foundation
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 months
Participants take atogepant 60 mg daily for 3 months as preventive treatment for high-frequency episodic migraine.
1 baseline visit and 1 follow-up visit
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Patricia Pozo-Rosich, Jessica Ailani, Messoud Ashina...
https://pubmed.ncbi.nlm.nih.gov/37516125/Jamir Pitton Rissardo, Ana Letícia Fornari Caprara
https://pubmed.ncbi.nlm.nih.gov/36552072/Armando Perrotta, Maria Grazia Anastasio, Roberto De Icco...
https://pubmed.ncbi.nlm.nih.gov/28488755/Jessica Ailani, Richard B Lipton, Peter J Goadsby...
https://pubmed.ncbi.nlm.nih.gov/34407343/Rosaria Greco, Chiara Demartini, Anna Maria Zanaboni...
https://pubmed.ncbi.nlm.nih.gov/35179780/Roberto De Icco, Rosaria Greco, Chiara Demartini...
https://pubmed.ncbi.nlm.nih.gov/33587406/Hjalte H Andersen, Meg Duroux, Parisa Gazerani
https://pubmed.ncbi.nlm.nih.gov/25636687/Rosaria Greco, Roberto De Icco, Chiara Demartini...
https://pubmed.ncbi.nlm.nih.gov/33066724/Richard B Lipton, Patricia Pozo-Rosich, Andrew M Blumenfeld...
https://pubmed.ncbi.nlm.nih.gov/36396451/Rosaria Greco, Chiara Demartini, Anna Maria Zanaboni...
https://pubmed.ncbi.nlm.nih.gov/32967434/IRCCS National Neurological Institute "C. Mondino" Foundation
Lead Sponsor